Frederick L. Hall

Delta Air Lines (United States) — United States

Medicine · Health Sciences

43h-index4.8kcitations132works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(31), Virus-based gene therapy research(24), Ubiquitin and proteasome pathways(14), Cancer Research and Treatments(14), RNA Interference and Gene Delivery(10)

Publications132 total

Gene and Cell Therapy for Sarcomas: A Review
Cancers·2025· 1 citedOpen Access
1771P Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)
Annals of Oncology·2024Open Access
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.
Journal of Clinical Oncology·2024
Editorial: Celebrating the 200th mendel’s anniversary: gene-targeted diagnostics and therapies for cancer
Frontiers in Molecular Medicine·2024Open Access
From Mendel to Gene Therapy
Anticancer Research·2023· 1 citedOpen Access
Early-stage <i>CCNG1</i>+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a <i>CCNG1</i> Inhibitor
Anticancer Research·2023· 2 citedOpen Access
The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective
Frontiers in Molecular Medicine·2023Open Access
Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130)
Frontiers in Molecular Medicine·2022· 6 citedOpen Access
Two year results of blessed: Expanded access for deltarex-g for an intermediate size population with advanced pancreatic cancer and sarcoma (<i>NCT04091295) </i>and individual use IND for EARLY-STAGE invasive carcinoma of breast (<i>IND# 19130) </i>.
Journal of Clinical Oncology·2022
CCNG1 oncogene: a novel biomarker for cancer therapy /gene therapy
Cancer Research and Cellular Therapeutics·2021· 2 citedOpen Access
Polypeptidic Taxol-Tropins: Targeting paclitaxel to the tumor microenvironment
Cancer Research and Cellular Therapeutics·2021Open Access
Tumor protein p53 mutation in archived tumor samples from a 12‑year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long‑term survival with DeltaRex‑G: A case report and literature review
Molecular and Clinical Oncology·2021· 10 citedOpen Access
Biochemical Characterization of the Human Cyclin-dependent Protein Kinase Activating Kinase: IDENTIFICATION OF p35 AS A NOVEL REGULATORY SUBUNIT
UNC Libraries·2021Open Access
Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival
IntechOpen eBooks·2021Open Access
Our Journey Beyond Sunset Boulevard - Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on “True” Long-Term Cancer-Free Survival
IntechOpen eBooks·2021
Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy
IntechOpen eBooks·2021· 1 citedOpen Access
Digital Data Standards in Aircraft Asset Lifecycle: Current Status and Future Needs
SAE International Journal of Advances and Current Practices in Mobility·2021
Larkin: FDA Emergency Use Authorized Treatment Protocol of DeltaRex-G for Severe Covid-19 [IND# 27185]
European Journal of Respiratory Medicine·2021· 1 citedOpen Access
Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer
Integrative Journal of Medical Sciences·2021· 1 citedOpen Access
Survival data following phase 1/2 studies using precision tumor-targeted gene delivery to advanced chemotherapy-resistant malignancies.
Journal of Global Oncology·2019· 1 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Erlinda M. Gordon(21), Lingtao Wu(9), W. French Anderson(8), Marcel E. Nimni(6), D. A. Carbonaro-Hall(5), Philip R Vulliet(5), Bo Han(5), David Warburton(4), Michael J. Skotzko(4), Sant P. Chawla(4), Robert W. Beart(4), Richard T. Williams(3), R. T. Williams(3), Harold C. Slavkin(3), José A. Andrades(3), Susan Groshen(3), Nian Ling Zhu(3), David R. Hinton(3), Liqiong Liu(3), Ann Yee(3)